Browsing Tag
India pharma
2 posts
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.
Pfizer signs five-year marketing deal with Cipla for Corex, Dolonex, and Neksium in India
Pfizer Limited has partnered with Cipla Limited to market and distribute four major brands in India. Find out what this means for both companies and the industry.